ClinicalTrials.gg
RecruitingNCT07392957Updated Jun 22, 2026

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

A Phase 1/2 interventional study of CTX-009 and CTX-471 in Glioblastoma, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Washington University School of Medicine · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Glioblastoma by Washington University School of Medicine — 5 open to participants now, 7 under way, none of them phase 3. Glioblastoma · Washington University School of Medicine.

Planned enrollment
3rd of 16
54 · median 31
Started
2026
with 2 others
Phase 1/2
2 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Glioblastoma by Washington University School of Medicine, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1/2, and was the 17th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

5 of the 19 studies in Glioblastoma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Glioblastoma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma.

CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • VEGF
  • 4-1BB
  • CD137
  • glioblastoma
  • immunotherapy
  • targeted therapy
  • CTX-009
  • CTX-471
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or radiographically confirmed recurrent CNS WHO grade 4 IDH wild-type glioma following standard of care treatment including radiation, chemotherapy, and/or tumor-treating fields. No more than 2 recurrences are allowed.
  • Patients may receive palliative treatment for recurrent disease prior to study enrollment with surgery or laser thermal ablation but must wait at least 4 weeks post-procedure to start study drug(s) and must have recovered from all procedure-related complications.
  • At least 18 years of age.
  • performance status ≥ 60%
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1.0 K/cumm
    • ≥ 75 K/cumm
    • ≥ 8.0 g/dL
    • Total ≤ 1.5 x IULN, unless suspected or documented history of Gilbert's Syndrome, in which case ≤ 2.5 x IULN
    • (SGOT)/ALT(SGPT) ≤ 2.5 x IULN
    • > 30 mL/min by Cockcroft-Gault
    • Urine Protein : Creatinine ratio (UPCR) \< 300 mg/g
  • \< 480 msec; in the setting of bundle branch block or other arrhythmia that makes QTcF unreliable, a JT interval \< 350 msec can be used as a substitute.
  • The effects of CTX-009 and CTX-471 on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to study entry, for the duration of study participation, and for 4 months after completion of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.
  • Resolution, or stable control with medical management, of all prior anti-cancer therapy toxicities to ≤ grade 1 per v5.0. If the patient has had major surgery, 4 weeks must have elapsed from the date of surgery and the first dose of study drug(s).
  • Stable or decreasing dose of and anti-seizure medications for 7 days prior to start of study drug(s). For Arm 2: a maximum of 2 mg daily dose of dexamethasone or equivalent at time of study drug(s) initiation is allowed.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Have progressed on prior anti-VEGF-A therapy (i.e., bevacizumab) or developed adverse reaction to any anti-VEGF therapy (i.e., bevacizumab, regorafenib) which led to discontinuation of treatment. Prior treatment with low dose anti-VEGF therapy for management of symptomatic vasogenic edema or radiation necrosis is permitted as long as progression was not noted while receiving treatment with the anti-VEGF agent, and is not needed for continued control of symptoms. A 4-week washout from last dose of low-dose anti-VEGF therapy is required.
  • Prior systemic anti-cancer therapy including: agents or immunotherapy within 4 weeks (can consider 2 week interval for agents with known 5 half-lives \<14 days following discussion with study PI); chemotherapy within 4 weeks (6 weeks for BCNU or CCNU); or targeted therapy within 2 weeks prior to treatment.

Note: participants must have recovered from all clinically significant AEs due to previous therapies to ≤ grade 1 or baseline. This does not include AEs deemed not clinically significant by treating physician (i.e., alopecia). Participants with endocrine-related AEs ≤ grade 2 requiring treatment or hormone replacement are eligible if controlled (i.e., clinically asymptomatic) on stable dose of replacement therapy.

  • Use of aspirin, NSAIDs, or other antiplatelet agents within 7 days of study drug(s) initiation. Regular use (i.e., daily) of these agents should be avoided while on study treatment.
  • Use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes within 7 days of study drug(s) initiation. Prophylactic dosing of DOAC, such as apixaban or edoxaban, or LMWH for patency of venous access devices is allowed (preference is given to DOAC over LMWH).
  • History of intraparenchymal or subdural hemorrhage. History of hemorrhage-related or gastroenterological disease including active hemorrhage, hemorrhagic diathesis, coagulopathy, or tumor in great arteries. History of clinically significant gastroenterological disease, such as peptic ulcer, GI bleeding, GI or non-GI fistula, perforation, abdominal abscess, percutaneous drains, clinical symptoms and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease (IBD).
  • History of unprovoked high-risk thromboembolic events.
  • A history of the following cardiovascular diseases in the past 5 years (a case-by-case evaluation can be considered in consultation with the study PI):

    • Congestive heart failure that corresponds to Class II or a higher class under classification or \< 50% of
    • Uncontrolled hypertension (140/90 mmHg despite best care including anti-hypertensive medications). White coat hypertension is not exclusionary.
    • Hypertensive crisis or pre-existing hypertensive encephalopathy
    • Pulmonary hypertension
    • Myocardial infarction
    • Uncontrolled arrhythmia
    • Unstable angina
  • Significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to study entry
  • For Arm 2: Prior treatment with other investigational immune-oncology therapies targeting CD137 (4-1BB).
  • For Arm 2: Systemic therapy with non-steroidal agents within 7 days prior to first dose. Patients with a prior history of disease not requiring immunosuppressive therapy may be eligible following discussion with the study PI. Topical, intranasal, intraocular, or inhaled and physiologic replacement for patients with adrenal insufficiency are allowed.
  • Prior solid organ or hematologic cell transplantation.
  • For Arm 2: Has received a live or within 30 days prior to the first dose. Note: administration of killed vaccines is allowed.
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to CTX-009 or CTX-471.
  • Active uncontrolled seizure disorder.
  • Active uncontrolled intercurrent illness including, but not limited to: infection, hypertension, open wound(s), or cardiac arrhythmia. Chronic illnesses controlled (i.e., clinically asymptomatic) with oral medications are allowed.
  • Pregnant and/or breastfeeding. Women of must have a negative serum pregnancy test within 7 days of first dose for Arm 1 or 72 hours of first dose for Arm 2.
  • -infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
  • Evidence of chronic virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
  • History of virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Phase IB Arm 1: CTX-009 monotherapy

    CTX-009 will be given intravenously at the assigned dose level on an outpatient basis every 2 weeks of a 28-day cycle.

    Drug: CTX-009

  • Experimental
    Phase IB Arm 2: CTX-009 and CTX-471 combination therapy

    CTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) in Arm 1 every 2 weeks, and CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days.

    Drug: CTX-009 · Drug: CTX-471

  • Experimental
    Phase II Expansion Arm 1: CTX-009 monotherapy

    CTX-009 will be given intravenously at the recommended phase 2 dose (RP2D) determined from Phase IB on an outpatient basis every 2 weeks of a 28-day cycle.

    Drug: CTX-009

  • Experimental
    Phase II Expansion Arm 2: CTX-009 and CTX-471 combination therapy

    CTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) every 2 weeks (day 1 and day 15). CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days.

    Drug: CTX-009 · Drug: CTX-471

Interventions

  • DrugTovecimigStudies of TovecimigTovecimig pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CTX-009 will be given intravenously over the course of 60 minutes (+/- 5 minutes) on an outpatient basis every 2 weeks of a 28-day cycle.

    Also known as: Tovecimig

  • DrugCTX-471

    CTX-471 will be given intravenously over the course of 30 minutes (-5/+10) on an outpatient basis every 2 weeks of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Phase IB Arm 1: Toxicity as measured by number of participants with adverse events

    Adverse events will be graded according to CTCAE v6.0

    Time frame: Start of treatment through 60 days after treatment (estimated to be 14 months)

  2. Phase IB Arm 1: Recommended Phase 2 Dose (RP2D)

    RP2D will be determined from the phase IB portion of Arm 1 by assessing tolerability. Tolerability is defined as ≤1 among patients experiencing excessive dose limiting toxicities (DLTs). The dose level in phase IB determined to be tolerable is the RP2D.

    Time frame: Start of treatment through completion of cycle 1 (each cycle is 28 days)

  3. Phase IB Arm 2: Toxicity as measured by number of participants with adverse events

    Adverse events will be graded according to CTCAE v6.0

    Time frame: Start of treatment through 60 days after treatment (estimated to be 14 months)

  4. Phase II Arm 1: Overall survival rate at 12 months (OS12)

    Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.

    Time frame: 12 months

  5. Phase II Arm 2: Overall survival rate at 12 months (OS12)

    Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.

    Time frame: 12 months

Secondary outcomes

  1. Overall response rate (ORR)

    Overall Response Rate (ORR) is measured as the proportion of patients with complete response (CR) or partial response (PR) as defined by the RANO Response criteria. CR is defined as disappearance of all enhancing measurable and non-measurable disease for at least 4 weeks, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions, off corticosteroids and stable or improved clinically. PR is defined as ≥ 50% decrease of all measurable enhancing lesions for at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing (T2/FLAIR) lesions, corticosteroid dose no greater than dose at time of baseline scan, stable or improved clinically

    Time frame: Start of treatment to end of treatment (estimated total time to be 12 months)

  2. Duration of response (DoR)

    DoR is defined as time from Day 1 of study treatment (CTX-009 with our without CTX-471) to disease progression or death in patients who achieve a complete response (CR) or partial response (PR) as defined by the RANO criteria. CR is defined as disappearance of all enhancing measurable and non-measurable disease for at least 4 weeks, no new lesions, stable or improved non-enhancing (T2/FLAIR) lesions, off corticosteroids and stable or improved clinically. PR is defined as ≥ 50% decrease of all measurable enhancing lesions for at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing (T2/FLAIR) lesions, corticosteroid dose no greater than dose at time of baseline scan, stable or improved clinically. .

    Time frame: Start of treatment to disease progression/recurrence (estimated total time to be 36 months)

  3. Median progression-free survival (mPFS)

    mPFS is defined as the time of treatment start to the event of disease progression. Disease progression is measured based on the RANO criteria.

    Time frame: Start of treatment to disease progression (estimated to be 36 months)

  4. Median overall survival (mOS)

    mOS is measured as the amount of time from treatment start to death due to any cause or latest follow up, whichever is earlier.

    Time frame: Start of treatment through completion of follow up or death (estimated to be 36 months)

  5. Progression free survival at 9 months (PFS9)

    PFS9 is measured as amount of time from the start of treatment to the event of disease progression. Disease progression is measured based on the RANO criteria.

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Tanner M Johanns, MD, PhD · Contacttannerjohanns@wustl.edu · 314-362-9355
    • Tanner M Johanns, MD, PhD · Principal investigator
    • Jingqin R Luo, PhD · Sub investigator
    • Myung Sik Jeon · Sub investigator
    • Milan Chheda, MD · Sub investigator
    • Omar Butt, MD, PhD · Sub investigator
    • Julie Schutte, MSN, AFRN, FNP-C · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data will be shared that underlie the results reported (text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 36 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 6, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2031
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392957
Collaborators
Compass Therapeutics
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Jun 16, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jun 22, 2026

Study contacts

Tanner M Johanns, MD, PhD
Contact
tannerjohanns@wustl.edu
314-362-9355
Tanner M Johanns, MD, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovecimig

Start the discussion